Sep 18, 2017· Secondary Outcome Measures : . Characterize the pharmacokinetics (PK) profiles of LZM009 in blood specimens of subjects with at least 1 dose [ Time Frame: Predose, 0 h, 2 h, 6h, 24h, days 3, 8, 15 and 22 post infusion of cycle 1; predose of cycle 2 and 3; pre-dose, 0 h, 2 h, 6h, days 8, and 15 post infusion of cycle 4 and predose of every other cycle after Cycle 5(one cycle=21 days except ...